Study of Hospital-at-Home Care Compared to Hospital Monitoring for Adults Receiving Tarlatamab for Small Cell Lung Cancer

What this Trial Is About

This research aims to evaluate whether a Hospital-at-Home HaH program is a more efficient way to monitor the health of people with extensive stage small cell lung carcinoma after receiving tarlatamab treatment compared to traditional inpatient hospital monitoring. The study is sponsored by Memorial Sloan Kettering Cancer Center and focuses on improving health services delivery for patients undergoing this therapy. Participants are randomly assigned to one of two groups the control group receiving tarlatamab as usual care in the hospital, and the intervention group receiving tarlatamab through a hospital-at-home care model. In the HaH group, a SeniorCare community paramedic visits the patients home or residence after discharge to support care. This study compares these two approaches to determine which better manages patient health during treatment. During the study, participants will be monitored for the number of inpatient hospital days within 14 days as the primary outcome measure. Researchers will assess health status through regular monitoring and care delivery either at home or in the hospital. The total participation duration may vary depending on treatment and monitoring needs, with ongoing assessments to understand the impact of home-based care on patient outcomes.

A Study of Hospital-at-Home for People Receiving Tarlatamab